Drug assessment at a glance: A26-63[1]

Clascoterone (acne vulgaris)

6 November 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-63. The GBA decides on the added benefit.

Research question for the benefit assessment

Population	Adults with acne vulgaris and adolescents from 12 to <18 years of age with facial acne vulgaris
Intervention	clascoterone
Comparator	▪ Topical combination therapy of adapalene + benzoyl peroxide or ▪ Topical combination therapy of clindamycin + benzoyl peroxide or ▪ Topical combination therapy of clindamycin + tretinoin
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects		Informative value of the effects	
Mortality	∅		–	
Morbidity	∅		–	
Symptoms	∅		–	
Health-related quality of life	∅		–	
Side effects	∅		–	
	∅	No (suitable) data	–	Not applicable
	↔	No advantage or disadvantage	★	Low
	↑ / ↓	Small advantage/disadvantage	★★	Moderate
	↑↑ / ↓↓	Moderate advantage/disadvantage	★★★	High
	↑↑↑ / ↓↓↓	Large advantage/disadvantage		

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No relevant study was identified.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Clascoteron (Acne vulgaris); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 25.08.2026]. URL: https://doi.org/10.60584/A26-63.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Wirkstoff Clascoteron (Akne vulgaris; ≥ 12 Jahre) [online]. 2026 [Accessed:25.08.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1353/.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-63.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de